Claris

Menu
  • About Us
    • Company Overview
    • Milestones
  • Investors
    • Financials
    • Corporate Governance
    • Board of Directors' Profile
    • Shareholding Pattern
    • Notices/ Results
    • Registrar & Transfer Agent
    • Investor Contact
    • Unclaimed Dividend
    • Policies and Codes
    • Letter of appointment to Independent Directors
  • Media
    • Press Room
    • Media Contact
    • Media Gallery
  • Career
    • Overview
    • Culture
    • Current Openings
    • Apply
  • Contact Us
  • Claris Lifesciences Limited
  • Media
  • Press Room 2019
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
    • 2012
    • 2011
    • 2010
    • 2009
    • 2008
  • Media Contact
  • Media Gallery

Press Room 2014

December
Global Business Reports - India covers Mr. Arjun Handa, MD & CEO, in India Pharmaceuticals 2015

Claris Lifesciences Limited confirms patent challenge for its generic version of PROPOFOL in the USA

Half Marathon Amdavad, powered by Claris, receives roaring response

Half Marathon Amdavad, powered by Claris, receives roaring response
Half Marathon Amdavad, powered by Claris, receives roaring response


Launch event of Half Marathon Amdavad, powered by Claris

Launch event of Half Marathon Amdavad, powered by Claris
Launch event of Half Marathon Amdavad, powered by Claris


November
Unaudited Financial Results for the Quarter ended 30th September,2014

October
Claris Lifesciences Limited, completes transfer of its Speciality Injectable Business by way of a slump sale (as a going concern) to its wholly owned subsidiary viz. M/s. Claris Injectables Limited

August
Claris Lifesciences receives MHRA approval for New Plant

Unaudited Financial Results for the quarter ended 30th June, 2014

July
Claris Promoters in Business World’s ‘The Elite Club’

‘Greatness Diaries’ features interview of Claris' President - HRM & Corp. Communication

Claris Lifesciences Ltd received USFDA report stating it's finished dosage plant and API plant as acceptable

March
Unaudited Financial Results for the quarter ended 31st March, 2014

February
Audited Financial Results for the year ended 31st December 2013

January
ANDA Approval for Furosemide Injection in US

What’s New?

  • Claris completes sale of its Global Generic Injectables Business to Baxter
  • Financials
  • Notices/ Results
  • Annual Report 2016-17
Claris ClarisClaris
Useful Links
  • Home
  • About Us
  • Career
  • Contact Us
Investors
  • Financials
  • Board of Directors' Profile
  • Investor Contact
  • Policies and Codes
Media
  • Press Room
  • Media Contact
  • Media Gallery
India

Registered and Corporate Office:
Claris Corporate Headquarters
Nr. Parimal Crossing, Ellisbridge,
Ahmedabad - 380 006,
India.
Tel : + 91-79-26563331
CIN : U85110GJ1994PLC022543

  • Claris Lifesciences Ltd. All Rights Reserved.
  • Terms of Use
  • Privacy Policy